Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 11, 2013, Pages 861-867

  Koskimies, Pasi ^a   Turunen, Jari ^b   Lammintausta, Risto ^a   Scheinin, Mika ^c  

^a Hormos Medical Ltd   (Finland)

^b 4Pharma Ltd   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ospemifene; Pharmacokinetics; Postmenopausal; Selective estrogen receptor modulator

Indexed keywords

OSPEMIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEMALE; HEADACHE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA PROTEIN BINDING; POSTMENOPAUSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROTEIN BINDING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TISSUE DISTRIBUTION;

EID: 84887061821     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201925     Document Type: Article

References (15)

1. Nelson HD. Menopause. Lancet. 2008; 371: 760-770. CrossRef PubMed
2. North American Menopause Society . The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007; 14: 355-369.
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010; 85: 87-94. CrossRef PubMed
4. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med. 1992; 327: 620-627. CrossRef PubMed
5. Masood DE, Roach EC, Beauregard KG, Khalil RA. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab. 2010; 11: 693-714. CrossRef PubMed
6. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465-1477. CrossRef PubMed
7. Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs. 2001; 6: 137-154. CrossRef PubMed
8. Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol. 2005; 96: 15-25. CrossRef PubMed
9. Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs. 2009; 18: 839-849. CrossRef PubMed
10. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009; 6: 2133-2142. CrossRef PubMed
11. Unkila M, Kari S, Yatkin E, Lammintausta R. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013; 138C: 107-115. CrossRef PubMed
12. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002; 43: 207-214. CrossRef PubMed
13. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010; 17: 480-486. PubMed
14. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year longterm safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013; 20: 418-427. PubMed
15. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013; 20: 623-630. PubMed